Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence

Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis

Ablation vs Surgery for Small Kidney Tumors

Social Cue Prompts Reduce Sharing of Cancer Treatment Misinformation

Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes